Although we did not give accurate statistical results due to the limitation of samples, we found that GALNT9 was significantly lower expression in LGG, glioblastoma (GBM), cervical Cancer (CESC), colon Cancer (COAD), kidney chromophotoma (KICH), kidney papillary cell carcinoma (KIRP), thyroid cancer (THCA), and higher expression in thymoma (THYM) than in normal tissue in the public database GEPIA (Figure S10C). Here, GALNT9 is linked to cervical carcinoma.